HYDROXYZINE PAMOATE capsule

Pajjiż: Stati Uniti

Lingwa: Ingliż

Sors: NLM (National Library of Medicine)

Ingredjent attiv:

HYDROXYZINE PAMOATE (UNII: M20215MUFR) (HYDROXYZINE - UNII:30S50YM8OG)

Disponibbli minn:

TYA Pharmaceuticals

INN (Isem Internazzjonali):

HYDROXYZINE PAMOATE

Kompożizzjoni:

HYDROXYZINE 25 mg

Rotta amministrattiva:

ORAL

Tip ta 'preskrizzjoni:

PRESCRIPTION DRUG

Indikazzjonijiet terapewtiċi:

For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. Hydroxyzine may potentiate meperidine (Demerol

Sommarju tal-prodott:

NDC:64725-0169-1 in a CONTAINER of 15 CAPSULES

L-istatus ta 'awtorizzazzjoni:

Abbreviated New Drug Application

Karatteristiċi tal-prodott

HYDROXYZINE PAMOATE - HYDROXYZINE PAMOATE CAPSULE
TYA PHARMACEUTICALS
----------
RX ONLY
DESCRIPTION
Hydroxyzine pamoate is a light yellow odorless powder, practically
insoluble in water and methanol
and freely soluble in dimethylformamide. It is chemically designated
as (±)-2-[2-[4-( -Chloro-α-
phenylbenzyl)-1-piperazinyl]ethoxy] ethanol
4,4'-methylenebis[3-hydroxy-2-naphthoate] (1:1) and can be
structurally represented as follows: _p_
Chemical Formula: C H ClN O . C H O Molecular Weight: 763.29 Inert
ingredients for the capsule
formulations are: hard gelatin capsules (which contain gelatin,
titanium dioxide, FD&C Blue #1, FD&C
Red #40, D&C Yellow #10), printing ink which contains shellac glaze
~45% (20% esterified) in
Ethanol, iron oxide black, n-butyl alcohol, isopropyl alcohol,
propylene glycol and ammonium
hydroxide 28%); magnesium stearate, microcrystalline cellulose,
pregelatinized starch, sodium lauryl
sulfate, sodium starch glycolate.
CLINICAL PHARMACOLOGY
Hydroxyzine pamoate is unrelated chemically to the phenothiazines,
reserpine, meprobamate, or the
benzodiazepines. Hydroxyzine pamoate is not a cortical depressant, but
its action may be due to a
suppression of activity in certain key regions of the subcortical area
of the central nervous system.
Primary skeletal muscle relaxation has been demonstrated
experimentally. Bronchodilator activity, and
antihistaminic and analgesic effects have been demonstrated
experimentally and confirmed clinically. An
antiemetic effect, both by the apomorphine test and the veriloid test,
has been demonstrated.
21272223166
Pharmacological and clinical studies indicate that hydroxyzine in
therapeutic dosage does not increase
gastric secretion or acidity and in most cases has mild antisecretory
activity. Hydroxyzine is rapidly
absorbed from the gastrointestinal tract and hydroxyzine pamoate's
clinical effects are usually noted
within 15 to 30 minutes after oral administration.
INDICATIONS
For symptomatic relief of anxiety and tension associated with
psychoneurosis and as a